PATENT COOPERATION TREATY
`
`PCT
`
`INTERNATIONAL SEARCH REPORT
`
`(PCT Article 18 and Rules 43 and 44)
`
`Applicant's or agent's file reference
`zI919098-GWsv
`
`FOR FURTHER
`ACTION
`
`see Form PCT/ISA/220
`as well as, where applicable, item 5 below.
`
`International application No.
`
`Internationalfiling date (day/month/year)
`
`(Earliest) Priority Date (day/month/year)
`
`PCT/EP2020/075541
`
`11 September 2020 (11-09-2020)
`
`13 September 2019 (13-09-2019)
`
`Applicant
`
`KATHOLIEKE UNIVERSITEIT LEUVEN
`
`sheets.
`This international search report consists of a total of
`It is also accompanied by a copy of each prior art documentcited in this report.
`
`1. Basis of the report
`a. With regard to the language,the international search was carried out on the basis of:
`the international application in the language in whichit wasfiled
`, which is the language
`atranslation of the international application into
`of a translation furnished for the purposesof international search (Rules 12.3(a) and 23.1 (b))
`b.[] This international search report has been established taking into account the rectification of an obvious mistake
`authorized by or notified to this Authority under Rule 91 (Rule 43.6 bis(a)).
`
`[J
`
`With regard to any nucleotide and/or amino acid sequencedisclosedin the international application, see Box No. I.
`
`Certain claims were found unsearchable (See Box No. II)
`
`[] Unity of invention is lacking (see Box NoIII)
`
`4. With regard to thetitle,
`
`the text is approved as submitted by the applicant
`the text has been established by this Authority to read as follows:
`
`[|
`
`5. With regard to the abstract,
`
`[|
`
`the text is approved as submitted by the applicant
`the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant
`may, within one month from the date of mailing of this international search report, submit comments to this Authority
`
`6. With regard to the drawings,
`
`This international search report has been prepared bythis International Searching Authority and is transmitted to the applicant
`according to Article 18. A copyis being transmitted to the International Bureau.
`6
`
`noneofthe figures is to be published with the abstract
`
`a.
`
`the figure of the drawings to be published with the abstract is Figure No.
`as suggested by the applicant
`[] as selected by this Authority, because the applicantfailed to suggest a figure
`[] as selected by this Authority, because this figure better characterizes the invention
`b. []
`
`4b
`
`Form PCT/ISA/210 (first sheet) (January 2015)
`
`

`

`INTERNATIONAL SEARCH REPORT
`
`International application No.
`
`PCT/EP2020/075541
`
`Box No. |
`
`Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)
`
`With regard to any nucleotide and/or amino acid sequencedisclosedin the international application, the international search was
`carried out on the basis of a sequencelisting:
`
`a.
`
`forming part of the international application asfiled:
`
`inthe form of an Annex C/ST.25 textfile.
`
`In addition, in the case that more than one version or copy of a sequencelisting has beenfiled or furnished, the required
`statements that the information in the subsequentor additional copies is identical to that forming part of the application as
`filed or does not go beyond the application as filed, as appropriate, were furnished.
`
`Additional comments:
`
`[] on paperorin the form of an imagefile.
`furnished together with the international application under PCT Rule 13ter.1(a) for the purposesof international search
`only in the form of an Annex C/ST.25textfile.
`
`furnished subsequentto the internationalfiling date for the purposesof international search only:
`
`[] in the form of an Annex C/ST.25text file (Rule 13ter.1(a)).
`[] on paperorin the form of an imagefile (Rule 13%ér.1(b) and Administrative Instructions, Section 71 3).
`
`[|
`
`Form PCT/ISA/210 (continuation offirst sheet (1)) (January 2015)
`
`

`

`A. CLASSIFICATION OF SUBJECT MATTER
`INV. A61K39/12
`A61P31/14
`ADD.
`
`According to International Patent Classification (IPC) or to both national classification and IPC
`B. FIELDS SEARCHED
`Minimum documentation searched (classification system followed by classification symbols)
`A61K A61P
`C12N
`
`PCT/EP2020/075541
`
`Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
`
`Electronic data base consulted during the international search (nameof data base and, where practicable, search terms used)
`
`EPO-Internal, WPI Data, Sequence Search
`
`INTERNATIONAL SEARCH REPORT International application No
`
`"Yellow fever
`XIAOHONG JIANG ET AL:
`17D-vectored vaccines expressing Lassa
`virus GPl and GP2 glycoproteins provide
`protection against fatal disease in guinea
`Pigs",
`VACCINE, ELSEVIER, AMSTERDAM, NL,
`vol. 29, no. 6,
`24 November 2010 (2010-11-24), pages
`1248-1257, XP028175836,
`ISSN: 0264-410X, DOI:
`10.1016/J.VACCINE.2010.11.079
`[retrieved on 2010-11-29]
`cited in the application
`abstract; Figs. 1, 7; page 1253
`
`C, DOCUMENTS CONSIDEREDTO BE RELEVANT
`
`Category*
`
`Citation of document, with indication, where appropriate, of the relevant passages
`
`Relevant to claim No.
`
`1-15
`
`Further documentsarelisted in the continuation of Box C.
`
`“ Special categories of cited documents :
`
`"A" documentdefining the general state of the art which is not considered
`to be of particular relevance
`"E" earlier application or patent but published on orafter the international
`filing date
`"L" document which maythrow doubts on priority claim(s) or whichis
`cited to establish the publication date of another citation or other
`special reason (as specified)
`"O" documentreferring to an oral disclosure, use, exhibition or other
`means
`"P" documentpublishedprior to the internationalfiling date but later than
`the priority date claimed
`
`|
`.
`|
`|
`|
`"T" later document publishedafter the internationalfiling date or priority
`date and notin conflict with the application but cited to understand
`the principle or theory underlying the invention
`
`"xX" documentof particular relevance; the claimed invention cannot be
`considered novel or cannot be consideredto involve an inventive
`step when the documentis taken alone
`"Y" documentof particular relevance; the claimed invention cannotbe
`consideredto involve an inventive step when the documentis
`combined with one or more other such documents, such combination
`being obvious to a person skilled in the art
`
`"&" document memberof the same patent family
`
`Date of the actual completion of the international search
`
`Date of mailing of the international search report
`
`14 December 2020
`Nameand mailing address of the ISA/
`European Patent Office, P.B. 5818 Patentlaan 2
`NL - 2280 HV Rijswijk
`Tel. (+31-70) 340-2040,
`Fax: (+31-70) 340-3016
`Form PCT/ISA/210 (second sheet) (April 2005)
`
`19/01/2021
`Authorized officer
`
`Heder, Andreas
`
`page 1 of 3
`
`

`

`
`
`
`
`INTERNATIONAL SEARCH REPORT
`
`
`
`PCT/EP2020/075541
`
`Category”
`
`Citation of document, with indication, where appropriate, of the relevant passages
`
`Relevant to claim No.
`
`"A recombinant
`BREDENBEEK P J ET AL:
`Yellow Fever 17D vaccine expressing Lassa
`virus glycoproteins",
`VIROLOGY, ELSEVIER, AMSTERDAM, NL,
`vol. 345, no. 2,
`20 February 2006 (2006-02-20), pages
`299-304, XP024896770,
`ISSN: 0042-6822, DOI:
`10.1016/J.VIROL.2005.12.001
`[retrieved on 2006-02-20]
`cited in the application
`abstract; Figs. 1, 4; page 300
`
` International application No
`
`"Structural
`KATHRYN M. HASTIE ET AL:
`basis for antibody-mediated neutralization
`of Lassa virus",
`SCIENCE,
`vol. 356, no. 6341,
`2 June 2017 (2017-06-02), pages 923-928,
`XP055552501,
`US
`ISSN: 0036-8075, DOI:
`10.1126/science.aam/260
`cited in the application
`
`"A ML29 reassortant virus
`CARRION ET AL:
`protects guinea pigs against a distantly
`related Nigerian strain of Lassa virus and
`can provide sterilizing immunity",
`VACCINE, ELSEVIER, AMSTERDAM, NL,
`vol. 25, no. 20,
`24 April 2007 (2007-04-24), pages
`4093-4102, XP022046892,
`ISSN: 0264-410X, DOI:
`10.1016/J.VACCINE. 2007 .02.038
`
`(GEOVAX INC)
`WO 2019/018501 Al
`24 January 2019 (2019-01-24)
`sequence 10
`& DATABASE Geneseq [Online]
`
`21 March 2019 (2019-03-21),
`"Lassa virus Josiah glycoprotein (GP)
`mutant SEQ ID 10.",
`retrieved from EBI accession no.
`GSP:BGB16546
`Database accession no. BGB16546
`sequence
`
`(FUND OSWALDO CRUZ [BR])
`EP 3 498 850 Al
`19 June 2019 (2019-06-19)
`sequence 8
`
`-/--
`
`5,10,11
`
`Form PCT/ISA/210 (continuation of second sheet) (April 2005)
`
`page 2 of 3
`
`

`

`
`
`
`
`Category”
`
`International application No
`
`PCT/EP2020/075541
`
`
`
`
`
`
`Citation of document, with indication, where appropriate, of the relevant passages
`
`& DATABASE Geneseq [Online]
`
`Relevant to claim No.
`
`
`
`5 April 2018 (2018-04-05),
`"Yellow fever virus derived polyprotein
`HAc, SEQ ID 8.",
`retrieved from EBI accession no.
`GSP:BFC19731
`Database accession no. BFC19731
`sequence
`
` INTERNATIONAL SEARCH REPORT
`
`Form PCT/ISA/210 (continuation of second sheet) (April 2005)
`
`page 3 of 3
`
`

`

`Patent document
`cited in search report
`
`Publication
`date
`
`Patent family
`member(s)
`
`Publication
`date
`
`PCT/EP2020/075541
`
` International application No
`
`INTERNATIONAL SEARCH REPORT
`
`Information on patent family members
`
`WO 2019018501==Al 24-01-2019 US 2020171141 Al 04-06-2020
`
`
`
`
`
`WO
`2019018501 Al
`24-01-2019
`
`BR 102016018430 A2
`EP
`3498850
`US
`2019276500 Al
`WO
`2018027290 Al
`
`27-02-2018
`19-06-2019
`12-09-2019
`15-02-2018
`
`Al
`
`19-06-2019
`
`Form PCT/ISA/210 (patent family annex) (April 2005)
`
`